{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:23:29Z","timestamp":1794050609089,"version":"4.8.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274184"],"award-info":[{"award-number":["82274184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.apsb.2024.12.038","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:13:19Z","timestamp":1735672399000},"page":"1497-1513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ginsenoside CK targets PHD2 to prevent platelet adhesion and enhance blood circulation by modifying the three-dimensional arrangement of collagen"],"prefix":"10.1016","volume":"15","author":[{"given":"Chuanjing","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9161-2173","authenticated-orcid":false,"given":"Gang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.12.038_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2024.12.038_bib2","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.apsb.2022.01.004","article-title":"Engineered platelets-based drug delivery platform for targeted thrombolysis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.12.038_bib3","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2024.12.038_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2002-12-3882","article-title":"Platelet-collagen interaction: is GPVI the central receptor?","volume":"102","author":"Nieswandt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.12.038_bib5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1046\/j.1538-7836.2003.00245.x","article-title":"Activation of GPVI by collagen is regulated by \u03b12\u03b21 and secondary mediators","volume":"1","author":"Atkinson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.apsb.2024.12.038_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1096\/fj.04-1940fje","article-title":"Adhesion of human and mouse platelets to collagen under shear: a unifying model","volume":"19","author":"Auger","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2024.12.038_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012174","article-title":"Efficient inhibition of collagen-induced platelet activation and adhesion by LAIR-2, a soluble Ig-like receptor family member","volume":"5","author":"Lenting","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2024.12.038_bib8","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/01.ATV.0000193568.71980.4a","article-title":"The glycoprotein VI\u2013phospholipase C\u03b32 signaling pathway controls thrombus formation induced by collagen and tissue factor in\u00a0vitro and in\u00a0vivo","volume":"25","author":"Munnix","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2024.12.038_bib9","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.2174\/138161207781662867","article-title":"Inhibition of platelet glycoprotein Ib and its antithrombotic potential","volume":"13","author":"Vanhoorelbeke","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2024.12.038_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/hq0202.102321","article-title":"Inhibition of platelet glycoprotein Ib, glycoprotein IIb\/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons","volume":"22","author":"Wu","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2024.12.038_bib11","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V99.10.3623","article-title":"Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in\u00a0vivo arterial platelet thrombus formation in baboons","volume":"99","author":"Wu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.12.038_bib12","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/j.1538-7836.2006.02111.x","article-title":"von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen","volume":"4","author":"Bonnefoy","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.apsb.2024.12.038_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/ars.2009.2901","article-title":"Prolyl hydroxylases and therapeutics","volume":"12","author":"Smith","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.apsb.2024.12.038_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.apsb.2022.07.006","article-title":"Dihydrotanshinone I preconditions myocardium against ischemic injury via PKM2 glutathionylation sensitive to ROS","volume":"13","author":"Wu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.12.038_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2024.12.038_bib16","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.apsb.2023.06.002","article-title":"Functional annotation map of natural compounds in traditional Chinese medicines library: TCMs with myocardial protection as a case","volume":"13","author":"Xing","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.12.038_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116697","article-title":"Bioactive components and molecular mechanisms of Salvia miltiorrhiza Bunge in promoting blood circulation to remove blood stasis","volume":"317","author":"Wei","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2024.12.038_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105263","article-title":"Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy","volume":"161","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2024.12.038_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jgr.2021.09.003","article-title":"Panax ginseng: inflammation, platelet aggregation, thrombus formation, and atherosclerosis crosstalk","volume":"46","author":"Lee","year":"2022","journal-title":"J Ginseng Res"},{"key":"10.1016\/j.apsb.2024.12.038_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.apsb.2017.12.010","article-title":"Integrated metabolomic and transcriptomic analyses revealed the distribution of saponins in Panax notoginseng","volume":"8","author":"Wei","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.12.038_bib21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/jssc.200700507","article-title":"Screening of anti-platelet aggregation agents from Panax notoginseng using human platelet extraction and HPLC-DAD\u2013ESI-MS\/MS","volume":"31","author":"Wang","year":"2008","journal-title":"J Sep Sci"},{"key":"10.1016\/j.apsb.2024.12.038_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.carbpol.2013.11.016","article-title":"Panax ginseng polysaccharide induces apoptosis by targeting Twist\/AKR1C2\/NF-1 pathway in human gastric cancer","volume":"102","author":"Li","year":"2014","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2024.12.038_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154992","article-title":"Ginsenoside CK targeting KEAP1\u2013DGR\/Kelch domain disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage","volume":"119","author":"Cheng","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.apsb.2024.12.038_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpba.2017.12.011","article-title":"Metabolic analysis of Panax notoginseng saponins with gut microbiota-mediated biotransformation by HPLC-DAD\u2013Q-TOF\u2013MS\/MS","volume":"150","author":"Chen","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.apsb.2024.12.038_bib25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.immuni.2019.11.005","article-title":"Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure","volume":"51","author":"Yang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2024.12.038_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1679\/aohc.71.37","article-title":"The modulation of collagen fibril assembly and its structure by decorin: an electron microscopic study","volume":"71","author":"Iwasaki","year":"2008","journal-title":"Arch Histol Cytol"},{"key":"10.1016\/j.apsb.2024.12.038_bib27","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1074\/jbc.M109.068726","article-title":"Location of 3-hydroxyproline residues in collagen types I, II, III, and V\/XI implies a role in fibril supramolecular assembly","volume":"285","author":"Weis","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2024.12.038_bib28","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1021\/acs.jmedchem.3c00231","article-title":"Preferred conformation-guided discovery of potent and orally active HIF prolyl hydroxylase 2 inhibitors for the treatment of anemia","volume":"66","author":"Wu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.12.038_bib29","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1161\/CIRCULATIONAHA.107.760785","article-title":"Short hairpin RNA interference therapy for ischemic heart disease","volume":"118","author":"Huang","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2024.12.038_bib30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCULATIONAHA.117.027290","article-title":"Potent thrombolytic effect of N-acetylcysteine on arterial thrombi","volume":"136","author":"Martinez de Lizarrondo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2024.12.038_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0174-173X(82)80021-6","article-title":"Multiple collagen gene expression with type III predominance in rat mucosal keratinocytes","volume":"2","author":"Birkedal-Hansen","year":"1982","journal-title":"Coll Relat Res"},{"key":"10.1016\/j.apsb.2024.12.038_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2024.12.038_bib33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","article-title":"Vadadustat: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2024.12.038_bib34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","article-title":"Daprodustat: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2024.12.038_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ab.2004.09.019","article-title":"A fluorescence-based assay for 2-oxoglutarate-dependent oxygenases","volume":"336","author":"McNeill","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.apsb.2024.12.038_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2011.96","article-title":"The evolution of antiplatelet therapy in cardiovascular disease","volume":"8","author":"Yousuf","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2024.12.038_bib37","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.96.8.2751","article-title":"Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"96","author":"Hennekens","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2024.12.038_bib38","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2024.12.038_bib39","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.12.038_bib40","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","article-title":"Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"284","author":"Bhatt","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2024.12.038_bib41","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s10787-022-01010-1","article-title":"Phosphodiesterase (PDE) III inhibitor, cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP\/CREB pathway","volume":"30","author":"Khalifa","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.apsb.2024.12.038_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCINTERVENTIONS.111.966176","article-title":"New directions in antiplatelet therapy","volume":"5","author":"Ferreiro","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.apsb.2024.12.038_bib43","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)\u03b2: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3K\u03b2 inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.apsb.2024.12.038_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/ATVBAHA.114.303410","article-title":"Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease","volume":"35","author":"Flaumenhaft","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2024.12.038_bib45","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC-4: a novel \u03b1IIb\u03b23 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2024.12.038_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/01.RES.0000232317.84122.0c","article-title":"Conformation-specific blockade of the integrin GPIIb\/IIIa: a novel antiplatelet strategy that selectively targets activated platelets","volume":"99","author":"Schwarz","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.apsb.2024.12.038_bib47","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2024.12.038_bib48","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/jcph.1616","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of glenzocimab (ACT017) a glycoprotein VI inhibitor of collagen-induced platelet aggregation","volume":"60","author":"Renaud","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2024.12.038_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/hq0202.102321","article-title":"Inhibition of platelet glycoprotein Ib, glycoprotein IIb\/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons","volume":"22","author":"Wu","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2024.12.038_bib50","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2024.12.038_bib51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in\u00a0vitro and in\u00a0vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.apsb.2024.12.038_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH06-10-0582","article-title":"The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time","volume":"98","author":"Wadanoli","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.apsb.2024.12.038_bib53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1055\/s-0038-1653771","article-title":"Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries","volume":"73","author":"Azzam","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.apsb.2024.12.038_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/md18040178","article-title":"Comprehensive assessment of nile tilapia skin (Oreochromis niloticus) collagen hydrogels for wound dressings","volume":"18","author":"Ge","year":"2020","journal-title":"Mar Drugs"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524004957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:23:32Z","timestamp":1744975412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524004957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2211383524004957"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.12.038","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ginsenoside CK targets PHD2 to prevent platelet adhesion and enhance blood circulation by modifying the three-dimensional arrangement of collagen","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}